Objective: To investigate the relationship between 755 T>G polymorphisms in the CTNND 1 gene, which is associated with the risk of pancreatic carcinoma in Chinese. Methods: CTNND 1 755 T>G genotypes were determined by PCR-RFLP in 122 pancreatic carcinoma patients and 180 healthy controls matched for age and sex, who did not receive radiotherapy or chemotherapy for newly diagnosed and histopathologically confirmed pancreatic carcinoma. Results: In control subjects, the frequency of T/T and G/T genotypes, and T and G alleles was 79.4%, 17.2%, 88.1%, and 11.9%, respectively. The distribution of genotypes and allelotypes in the pancreatic carcinoma patients was significantly different from that in the controls (P = 0.007, P = 0.012). Combined GG and GT genotypes were found to have a higher OR in male pancreatic carcinoma patients and the group under the age of 70 years (males: OR, 1.409; 95%CI, 0.912~1.921; under 70 years: OR 1.626; 95% CI, 0.878~2.312). This study also showed a distinct difference in the distribution of P120ctn and single nucleotide polymorphisms (SNPs) between Chinese and Canadian (11.9% vs. 3.9%, P = 0. 008). Conclusion: CTNND 1 755 T>G polymorphism may be a stratification marker to predict the susceptibility to pancreatic carcinoma, at least in Chinese. CTNND 1 promoter SNPs is diverse in ethnic populations.
INTRODUCTION
Pancreatic carcinoma is a relatively rare tumor, and the lifetime risk of dying from pancreatic carcinoma is between 1% and 2% of the general population. In China, the incidence of pancreatic cancer has been rising during the past years, currently varying from 0.47/ 100,000 in the Hunan Province to 7.21/100,000 in Shanghai, representing the sixth leading cause of death from malignant disease (1) . Because symptoms typically remain absent until late in the course of disease, most cancers are detected at an advanced stage when prognosis is poor (2) . Therefore, it is important to investigate the genetic and epigenetic variation in susceptibility to pancreatic carcinogenesis and identify the markers that will facilitate identification of individuals at risk of pancreatic carcinogenesis.
DNA methylation is a major epigenetic modification involving the addition of a methyl group to the 5 0 position of a cytosine in a CpG dinucleotide.
A number of studies suggested that aberrant DNA cytosine methylation may play an important role in carcinogenesis (3, 4) . CTNND 1 is required for the establishment and maintenance of genomic methylation patterns and proper murine development (5, 6) . The gene is down-regulated to different degrees in some malignancies, including colon carcinoma, prostate carcinoma, and pancreatic carcinoma (7) (8) (9) (11) . Although conflicting results have been reported in different tumor types, the heterozygous genotypes have a significantly reduced risk of colon cancer and breast cancer (7, 11) . However, no report on the allele of CTNND 1 is available. This study was to investigate the polymorphism of CTNND 1 in pancreatic carcinoma.
MATERIALS AND METHODS

Study Population
This case-control study included 122 pancreatic carcinoma patients and 180 healthy controls. Pancreatic carcinoma was histopathologically confirmed in the 122 patients during surgery at the department of general surgery of our hospitals. The control subjects were selected from cancer-free subjects who visited the same hospital for a regular physical examination and volunteered to participate in the epidemiology survey during the same period. We defined a healthy subject as a person free of disease (including no history of cancer) at health check-up. The controls were matched for age and sex with the patients (Table 1 ). All patients and controls were ethnically Chinese and resided in Jiangsu Province or in its surrounding regions. The study protocol conformed to the guidelines by the institutional ethical committee. All patients gave their informed consent to be included in the study. The research was carried out according to the principles of The Declaration of Helsinki.
DNA Extract
Five milliliters of venous blood was drawn from each subject into vacuum tubes containing EDTA and stored at 4°C. Genomic DNA was extracted within 1 week after sampling by proteinase K digestion and salted out as previously described (12) .
CTNND 1 Genotyping
Transition from G to T of the CTNND 1 SNP creates a MvaI restriction site which can be exploited for genotyping by PCR and subsequent restriction fragment length polymorphism (RFLP) analysis. PCR was performed in a volume of 25 containing 100 ng of DNA template, 10 9 PCR master mix (Promega, Madison, WI), and 10 pmol/L each of sense primer (5 0 -GAGGTCTCGCATGCCTAGG-3 0 ) and antisense primer (5 0 -GGGA GCTCACCTTCTAGAAA-3 0 ). For PCR amplification, an initial denaturation at 94°C for 5 min was followed by 30 cycles at 94°C for 30 sec, at 57°C for 30 sec, at 72°C for 30 sec, and a final extension at 72°C for 7 min. The PCR products were digested overnight with five units of MvaI (New England Biolabs, Beverly, MA) at 37°C and separated on 2% agarose gels. RFLP bands were visualized under UV light with ethidium bromide staining. The CTNND 1 T/T genotype was expected to show two DNA bands at the positions of 132 bp and 93 bp, whereas the G/G genotype was expected to show a single band (225 bp), and the heterozygote was expected to have three bands (225 bp, 132 bp,93 bp). For quality control, genotyping analysis was performed blindly with respect to case-control status and repeated twice for all subjects.
DNA Sequencing Analysis
To confirm the genotyping results, selected PCRamplified DNA samples were examined by DNA sequencing. The PCR fragments were recovered from agarose gel followed by purification with a DNA clean-up kit (Wizard SV Gel and PCR Clean-up System, Promega). DNA sequences of the PCR products were determined using the PCR sense primer with an Applied Biosystems model 377 sequencer (PE Applied Biosystems, Warrington, UK). The results of genotyping were 100% concordant.
Statistical Analysis
Patients and controls were compared using Student's t-test for continuous variables and chi square test for categorical variables. Hardy-Weinberg equilibrium was tested with a goodness-of-fit chi square test with one degree of freedom to compare the observed genotype frequencies with the expected genotype frequencies among the subjects. Comparison of the CTNND 1 genotype and allelotype distribution in the study groups was performed by means of contingency tables using chi square test or Fisher's exact test. The odds ratio (OR) and 95% confidence interval (CI) were calculated using an unconditional logistic regression model and adjusted for age and gender accordingly. P < 0.05 was considered statistically significant.
RESULTS
The demographics of the cases and controls enrolled in this study are shown in Table 1 . There were no significant differences in the mean age and sex distribution between cases and controls, suggesting that the matching based on these two variables was adequate. There was no evidence of a deviation from HardyWeinberg equilibrium among the cases or controls. The mean age of the patients and controls was 69.6 years (AE7.3 years; range, 52-84 years) and 63.2 years (AE8.1 years; range, 55-85 years), respectively. All the patients and controls were successfully genotyped for the CTNND 1 polymorphism (Fig. 1) . The genotyping by PCR-RFLP analysis was completely confirmed by DNA sequencing analysis, and the results of PCR-RFLP genotyping and sequencing analysis were also 100% concordant (Fig. 2) . The distribution of CTNND 1 755 T>G polymorphism was in Hardy-Weinberg equilibrium. The frequency of G allele in control subjects (11.9%) was different from that in the previous study among Canadian (3.9%). The distributions of CTNND 1 755 T>G genotypes in Chinese and Canadian are shown in Table 2 .
The distributions of CTNND 1 755 T>G genotypes in controls and patients are shown in Table 3 . The genotype distributions of the polymorphisms in the controls were in Hardy-Weinberg equilibrium. Significant deviation was observed in the genotype distributions of both polymorphisms between overall pancr eatic carcinoma patients and controls. The TT genotype was found to be the most frequent genotype in both cases (58.2%) and controls (79.4%). Frequencies of the GG genotype and the G allele were significantly higher among patients than controls (P = 0.007, P = 0.012). Then, we stratified the results by sex and age. Patients and controls were found to be different with respect to the genotype distribution (Table 4) . Combined GG and GT genotypes were found to have a higher OR in male pancreatic carcinoma patients and the group under the age of 70 years (males: OR, 1.409; 95% CI, 0.912~1.921; under 70 years: OR 1.626; 95% CI, 0.878~2.312). Moreover, combined GG and GT genotypes showed significant association between CTNND 1 755 T>G polymorphism and the risk of pancreatic carcinoma. susceptibility to the development of human cancers by modifying the transcriptional activation. Studies suggested that some variants in the promoter region of genes may affect either the expression or activity levels of enzymes and therefore may be mechanistically associated with cancer risk (4, 13, 14) . It has been recently shown that SNP of the CTNND 1 promoter 755 T>G (from exon 3 transcription start site) decreases the susceptibility of an individual to colon cancer and breast cancer (7, 11) , suggesting that CTNND 1 promoter 755 G>T polymorphism can be used as a risk factor for cancer to evaluate the population susceptible to tumors. However, it was also reported that there is no association between polymorphism of 755 T>G and prostate carcinoma. However, to the best of our knowledge, the relative significance of SNP in the genetic susceptibility to pancreatic carcinoma has not yet been disclosed. In this study, we investigated the influence of CTNND 1 polymorphisms on the risk of pancreatic carcinoma in a hospital-based case-control study. This is the first study of CTNND 1 polymorphism in pancreatic carcinoma. We investigated the influence of 755 T>G polymorphism in the CTNND 1 gene on the risk of pancreatic carcinoma. Individuals carrying G allele in the CTNND 1 gene were found to have a nearly consistent risk of pancreatic carcinoma compared with those carrying T allele. Then, we stratified the results by sex and age, patients and controls.
Combined GG and GT genotypes showed significant association between CTNND 1 755 T>G polymorphism and risk of esophagus cancer, suggesting that 755 T>G polymorphism in the CTNND 1 gene can be used as a marker of genetic susceptibility to pancreatic cancer. Our study showed that CTNND 1 polymorphism was associated with the risk of pancreatic carcinoma, and other studies reported a increased risk of colon and breast cancer in those harboring G allele. Since the different variants of CTNND 1 may alter catalytic activity and are expressed in a tissue-specific manner and the repression of CTNND 1 activity does not result in reexpression of all hypermethylated tumor suppressor genes in some cell systems, it is therefore important to explore the complex interplay of CTNND 1 in different tumor types.
In this study, a distinct difference was found in the distribution of CTNND 1 SNP between Chinese and Canadian. Additionally, the frequency of GT and GG genotype in Chinese was higher than that in Canadian. The great diversity in CTNND 1 SNP distribution in different ethnic populations remains unknown.
In conclusion, the CTNND 1 gene may be involved in the development of pancreatic carcinoma. Further studies with a larger sample are required to confirm our findings, to understand the role of CTNND 1 polymorphisms in determining the risk of pancreatic carcinoma, and to clarify the association of CTNND 1 polymorphism with pancreatic carcinoma in different ethnic populations. 
